INS and type 1 diabetes mellitus: In the CGM TIME trial, which involved 144 children with type 1 diabetes for at least 1 year, patients were treated using a sensor‐augmented personal insulin pump with the LGS function, and parents completed the HFS‐II questionnaire at baseline and after 12 months of treatment.